Kailera Therapeutics (KLRA) priced 39.06M shares at $16.00. The deal size was increased and priced at the high end of the range. Kailera is an advanced clinical-stage biotechnology company that says it is “focused on elevating the next era of obesity care.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRA: